Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-860-0045
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.51 million
Profitability
Miscellaneous
Employees71
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions
What is Concert Pharmaceuticals' stock symbol?
Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."
How were Concert Pharmaceuticals' earnings last quarter?
Concert Pharmaceuticals Inc (NASDAQ:CNCE) announced its quarterly earnings data on Thursday, February, 28th. The biotechnology company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.15. Concert Pharmaceuticals had a negative return on equity of 29.33% and a negative net margin of 533.31%. View Concert Pharmaceuticals' Earnings History.
When is Concert Pharmaceuticals' next earnings date?
What price target have analysts set for CNCE?
4 Wall Street analysts have issued 1-year target prices for Concert Pharmaceuticals' stock. Their forecasts range from $19.00 to $27.00. On average, they anticipate Concert Pharmaceuticals' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 40.0% from the stock's current price. View Analyst Price Targets for Concert Pharmaceuticals.
What is the consensus analysts' recommendation for Concert Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Concert Pharmaceuticals.
What are Wall Street analysts saying about Concert Pharmaceuticals stock?
Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (3/5/2019)
- 2. HC Wainwright analysts commented, "Our price target of $26/share is comprised of $16.38 from CTP-543 in AA + $3.04 from AVP-786 in AD agitation + $6.38 in cash and is based on a discounted cash flow analysis (2019-2026) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development stage biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing." (3/1/2019)
- 3. Mizuho analysts commented, "We do not see earnings as the most meaningful indicator of value for a development-stage biotech. More importantly, Concert continues its steady progress on the clinical development front. A key catalyst is expected in 4Q18 with top-line readouts from the phase 2a trial of CTP-543 in alopecia areata at the 4 mg and 8 mg doses. A protocol amendment is also planned to evaluate the highest 12 mg dose. We anticipate data from the high-dose cohort will likely read out in 4Q19." (8/2/2018)
Has Concert Pharmaceuticals been receiving favorable news coverage?
News stories about CNCE stock have been trending somewhat negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Concert Pharmaceuticals earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Concert Pharmaceuticals' key competitors?
Some companies that are related to Concert Pharmaceuticals include Puma Biotechnology (PBYI), Opko Health (OPK), Prestige Consumer Healthcare (PBH), Gossamer Bio (GOSS), Innoviva (INVA), Corcept Therapeutics (CORT), Aimmune Therapeutics (AIMT), Clovis Oncology (CLVS), Theravance Biopharma (TBPH), TherapeuticsMD (TXMD), Cambrex (CBM), Phibro Animal Health (PAHC), Apellis Pharmaceuticals (APLS), Esperion Therapeutics (ESPR) and Ra Pharmaceuticals (RARX).
What other stocks do shareholders of Concert Pharmaceuticals own?
Who are Concert Pharmaceuticals' key executives?
Concert Pharmaceuticals' management team includes the folowing people:
- Mr. Richard H. Aldrich Mba, Co-Founder & Chairman (Age 65)
- Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 59)
- Ms. Nancy Stuart, Chief Operating Officer (Age 61)
- Dr. James V. Cassella, Chief Devel. Officer (Age 64)
- Mr. Marc A. Becker, Chief Financial Officer (Age 47)
Who are Concert Pharmaceuticals' major shareholders?
Concert Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (8.00%), BlackRock Inc. (7.26%), Ingalls & Snyder LLC (5.04%), Dimensional Fund Advisors LP (4.82%), Dimensional Fund Advisors LP (4.82%) and First Manhattan Co. (4.48%). Company insiders that own Concert Pharmaceuticals stock include James V Cassella, Nancy Stuart, Richard Aldrich, Ronald W Barrett, Ryan Lynch and Value Fund L P Biotechnology. View Institutional Ownership Trends for Concert Pharmaceuticals.
Which institutional investors are selling Concert Pharmaceuticals stock?
CNCE stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Northern Trust Corp, Ingalls & Snyder LLC, GSA Capital Partners LLP, Bank of New York Mellon Corp, Tekla Capital Management LLC, Connor Clark & Lunn Investment Management Ltd. and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include James V Cassella and Nancy Stuart. View Insider Buying and Selling for Concert Pharmaceuticals.
Which institutional investors are buying Concert Pharmaceuticals stock?
CNCE stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, RTW Investments LP, First Manhattan Co., Millennium Management LLC, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Virginia Retirement Systems ET AL and BlackRock Inc.. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Richard Aldrich and Value Fund L P Biotechnology. View Insider Buying and Selling for Concert Pharmaceuticals.
How do I buy shares of Concert Pharmaceuticals?
Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Concert Pharmaceuticals' stock price today?
One share of CNCE stock can currently be purchased for approximately $17.14.
How big of a company is Concert Pharmaceuticals?
Concert Pharmaceuticals has a market capitalization of $403.29 million and generates $10.51 million in revenue each year. The biotechnology company earns $-56,020,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Concert Pharmaceuticals employs 71 workers across the globe.
What is Concert Pharmaceuticals' official website?
How can I contact Concert Pharmaceuticals?
Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]
MarketBeat Community Rating for Concert Pharmaceuticals (NASDAQ CNCE)
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
